SeaStar Medical

SeaStar Medical shareholders elected John Neuman to the board of directors and approved a revised omnibus incentive plan that increases authorized common shares from 207,046 to 896,546. They also confirmed WithumSmith+Brown as the independent auditor for the fiscal year ending December 31, 2026, and granted the board the right to adjourn the annual meeting if necessary. The stock last traded at $3.06 after a weekly gain of more than 16%, but is down roughly 68% year-to-date. SeaStar reported strong revenue growth in the first quarter of 2026, attributed to the product QUELIMMUNE, and has a current ratio of 2.73. » Plus sur de.investing.com

SeaStar Medical recorded a 69% revenue rise in the first quarter of 2026 to US$495,000, driven by increased use of the QUELIMMUNE therapy for pediatric acute kidney injury. Gross margin remained above 90% with stable operating expenses of US$4.1 million; net loss narrowed slightly to US$3.5 million. The customer base grew to 17 hospitals, and the company is targeting about US$2 million in revenue for 2026 and an expansion of adult clinical trials. Investors reacted cautiously; the stock fell 3.57% in premarket trading. » Plus sur de.investing.com

SeaStar Medical posted 69% revenue growth in Q1 2026 to $495,000, driven by rising adoption of the QUELIMMUNE therapy and expansion to 17 hospitals. Gross margin remained high at over 90%, net loss narrowed to $3.5 million, and earnings per share improved to -$0.90. Cash and equivalents increased 79% to $9.3 million following a capital raise; the stock rose slightly in after-hours trading. For 2026 the company targets roughly $2 million in net revenue and plans a moderate increase in R&D spending to support ongoing studies. » Plus sur de.investing.com